Table 3

Summary of all cardiovascular AEs and SAEs

Placebo (n =1544)Salmeterol (n=1542)FP (n=1552)SFC (n=1546)
All CV AEs
Patients with CV AE, n (%)281 (18)287 (19)306 (20)267 (17)
Rate* of CV AE (no of events)142 (466)141 (496)130 (462)110 (405)
Probability† of CV AE by 3 years, %24.222.724.320.8
Hazard ratio95% CIp Value
SFC vs placebo0.830.70 to 0.980.031
Salmeterol vs placebo0.960.82 to 1.130.629
FP vs placebo1.000.85 to 1.180.994
CV SAEs
Patients with CV SAE, n (%)176 (11)168 (11)180 (12)160 (10)
Rate* of CV SAE (no of events)75 (245)66 (234)66 (236)57 (209)
Probability† of CV SAE by 3 years, %15.413.614.712.5
Hazard ratio95% CIp Value
SFC vs placebo0.810.65 to 1.000.046
SAL vs placebo0.890.72 to 1.100.268
FP vs placebo0.940.76 to 1.150.542

  • ↵* Rate=number of events per 1000 treatment years.

  • ↵† Kaplan–Meier probability.

  • AEs, adverse events; CV, cardiovascular; FP, fluticasone propionate; SAEs, serious adverse events; SFC, salmeterol/fluticasone propionate combination.